Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573660 | 0.89 | MEN1 (0.44) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2383727 | 0.88 | DRD2 (0.51) | DRD2DRD4DRD3ALDH1A1RAB9A | |
| SCHEMBL12250952 | 0.87 | P2RY12 (0.41) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2384081 | 0.86 | TGFBR1 (0.41) | ALDH1A1RAB9ATGFBR1 | |
| SCHEMBL2385186 | 0.83 | MEN1 (0.43) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2383147 | 0.83 | MEN1 (0.45) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL12251100 | 0.82 | DRD2 (0.42) | DRD2DRD4DRD3ALDH1A1RAB9A | |
| SCHEMBL2384352 | 0.80 | MEN1 (0.42) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2381720 | 0.80 | TRPV1 (0.41) | ALDH1A1TGFBR1 | |
| SCHEMBL2384694 | 0.79 | TRPV1 (0.41) | ALDH1A1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | DRD2 4047/4885DRD4 4354/4885DRD3 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.